First in Human Study to Assess Safety and Efficacy of an Implantable Nitinol Device in the Treatment of Keratoconus

ConditionKeratoconus
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRecornea Srl

About this trial

This Study is a First In Human clinical investigation addressed to evaluate the safety and efficacy of a novel intra-corneal nitinol device (Investigational Medical Device: GROSSO® implant) for the treatment of advanced keratoconus disease of the eye.

Eligibility criteria

Qualifiers

Signed and dated informed consent form.

Male and female ≥ 18 years old.

Not recommended for ICRS.

Recommended for keratoplasty.

Disqualifiers

Inability of patient and/or relatives to understand the clinical investigation procedures and thus inability to give informed consent.

Untreated progressive KC.

Single functioning eye.

Other ocular diseases (eyelids malposition, uveitis, ocular hypertension, glaucoma, cataract, retinal disorders) or corneal surgeries (refractive corneal surgery, keratoplasty), except corneal crosslinking.

Trial design

Treatments tested in this trial

  • Nitinol net for intracorneal implant for keratoconus treatment

Treatment groups

12 Participants
are divided into 1 treatment group

Locations

2
Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS00168, RomaRoma, Italy
Spain
Instituto de Microcirugía Ocular de Barcelona (IMO)08035, BarcelonaBar, Spain

Sponsors and collaborators

Recornea Srl

Lead sponsor